Volume | 367,784 |
|
|||||
News | (1) | ||||||
Day High | 21.44 | Low High |
|||||
Day Low | 21.35 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Fusion Pharmaceuticals Inc | FUSN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
21.37 | 21.35 | 21.44 | 21.40 | 21.40 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,116 | 367,784 | $ 21.40 | $ 7,870,128 | - | 2.31 - 21.55 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:09:26 | 10 | $ 21.31 | USD |
Fusion Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.48B | 68.99M | - | 1.46M | -87.61M | -1.27 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Fusion Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FUSN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 21.23 | 21.49 | 21.20 | 21.37 | 652,748 | 0.13 | 0.61% |
1 Month | 21.30 | 21.55 | 20.97 | 21.34 | 1,229,893 | 0.06 | 0.28% |
3 Months | 12.14 | 21.55 | 9.09 | 18.37 | 2,233,009 | 9.22 | 75.95% |
6 Months | 4.02 | 21.55 | 3.75 | 15.37 | 1,468,680 | 17.34 | 431.34% |
1 Year | 3.86 | 21.55 | 2.31 | 14.66 | 783,098 | 17.50 | 453.37% |
3 Years | 8.50 | 21.55 | 1.98 | 12.73 | 321,972 | 12.86 | 151.29% |
5 Years | 18.50 | 21.55 | 1.98 | 12.84 | 271,041 | 2.86 | 15.46% |
Fusion Pharmaceuticals Description
Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others. |